급성관상동맥증후군 시장 규모, 점유율, 성장 분석 : 유형별, 진단별, 치료별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Acute Coronary Syndrome Market size was valued at USD 12.7 billion in 2024 and is poised to grow from USD 13.77 billion in 2025 to USD 26.25 billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The global acute coronary syndrome market is experiencing significant growth, driven by the rising prevalence of cardiovascular diseases linked to lifestyle factors such as sedentary habits, obesity, smoking, and hypertension. An aging population increases the incidence of cardiac events, particularly in regions with older demographics, enhancing market volume. Efforts to improve awareness through educational campaigns, innovative diagnostics, and upgraded emergency care infrastructure positively influence patient detection and treatment. The therapeutic landscape is evolving with new anticoagulants and antiplatelet therapies emerging, bolstered by increased investment in cardiac care from both government and private sectors, particularly in developing nations. However, challenges remain, including high treatment costs, strict regulatory environments for drug approvals, and disparities in healthcare access and skilled personnel in rural areas.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Coronary Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Coronary Syndrome Market Segments Analysis

Global Acute Coronary Syndrome Market is segmented by Type, Diagnosis, Treatment, End User and region. Based on Type, the market is segmented into Unstable Angina, ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI) and Others. Based on Diagnosis, the market is segmented into Blood Tests, Imaging, Stress Test and Others. Based on Treatment, the market is segmented into Medication, Surgery and Others. Based on End User, the market is segmented into Hospitals and Clinics, Diagnostic Centers, Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Coronary Syndrome Market

One of the key market drivers for the global acute coronary syndrome market is the increasing prevalence of cardiovascular diseases, which is largely fueled by lifestyle factors such as unhealthy diet, sedentary behavior, and rising levels of obesity. As more individuals experience risk factors associated with acute coronary syndrome, there is a heightened demand for advanced diagnostic tools and therapeutic interventions. Additionally, ongoing innovations in medical technology and pharmaceuticals aimed at improving patient outcomes and enhancing early detection capabilities further propel market growth. Increased awareness of cardiovascular health among the population also contributes positively to the market dynamics, driving demand for effective treatment options.

Restraints in the Global Acute Coronary Syndrome Market

One of the key market restraints for the global acute coronary syndrome market is the high cost of advanced diagnostic and therapeutic technologies. The expenses associated with cutting-edge treatments, including stents, cardiac surgery, and other interventional procedures, can limit accessibility for a significant portion of the population, particularly in developing regions. Additionally, stringent regulatory requirements and lengthy approval processes for new medications and devices can hinder market entry for innovative solutions. This financial barrier may lead to disparities in treatment availability, ultimately affecting patient outcomes and impeding overall market growth in the acute coronary syndrome sector.

Market Trends of the Global Acute Coronary Syndrome Market

The global acute coronary syndrome market is increasingly influenced by a shift towards personalized and precision medicine. This trend focuses on tailoring therapeutic strategies to individual patient profiles through advanced genetic testing, biomarker identification, and comprehensive risk assessment. By personalizing treatment options-ranging from medications to interventional procedures-healthcare providers aim to enhance efficacy while minimizing adverse effects. This approach not only improves patient outcomes but also fosters the development of targeted therapies, thereby facilitating long-term management and prevention of acute coronary events. As this trend gains momentum, it is expected to significantly reshape the landscape of acute coronary syndrome treatment globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Acute Coronary Syndrome Market Size by Type & CAGR (2026-2033)

• Market Overview
• Unstable Angina
• ST-Elevation Myocardial Infarction (STEMI)
• Non-ST-Elevation Myocardial Infarction (NSTEMI)
• Others

Global Acute Coronary Syndrome Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Blood Tests
• Imaging
• Stress Test
• Others

Global Acute Coronary Syndrome Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Medication
• Surgery
• Others

Global Acute Coronary Syndrome Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Diagnostic Centers
• Academic Institutes
• Others

Global Acute Coronary Syndrome Market Size & CAGR (2026-2033)

• North America (Type, Diagnosis, Treatment, End User)
  • US
  • Canada
• Europe (Type, Diagnosis, Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Diagnosis, Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Diagnosis, Treatment, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Diagnosis, Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (MSD)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Genentech)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Idorsia Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DalCor Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations